Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MT-2111 in Relapsed/Refractory DLBCL
NCT05658562Phase 2Active, not recruiting
- Sponsor
- Mitsubishi Tanabe Pharma
- Start
- Jan 2023
- Primary completion
- Aug 2028
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs)
- Countries
- 1
01
Overview
A Phase 2 trial of loncastuximab tesirine in diffuse large B-cell lymphoma (DLBCL), sponsored by Mitsubishi Tanabe Pharma. Started Jan 2023; status: active, not recruiting.
02
Drugs
loncastuximab tesirine
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT05658562.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05658562.